References
- Dahlöf B., Sever P. S., Poulter N. R., Wedel H., Beevers G., Caulfield M., et al. Prevention of cardiovascular events with an amlodipne+perindopril strategy compared with an atenolol+thiazide strategy. Anglo‐Scandinavian Cardiac Outcomes Trial – Blood Pressure‐Lowering Arm (ASCOT‐BPLA). Lancet 2005; 366: 895–906
- Poulter N. R., Wedel H., Dahlöf B., Sever P. S., Beevers G., Caulfield M., et al. The role of blood‐pressure reduction and of changes in other possible exlanatory variables in the differential cardiovascular event rates observed in the ASCOT‐BPLA trial. Lancet 2005; 366: 907–913
- Julius S., Kjeldsen S. E., Weber M., Brunner H., Ekman S., Hansson L., et al. Cardiac events, stroke and mortality in high‐risk hypertensives treated with valsartan or amlodipine: Main outcomes of The VALUE Trial. Lancet 2004; 363: 2022–2031
- Weber M., Julius S., Kjeldsen S. E., Brunner H., Ekman S., Hansson L., et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004; 363: 2049–2051
- Verdeccia P., Reboldi G., Angeli F., Gattobigio R., Bentivoglio M., Thijs L., et al. Angiotensin‐converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension 2005; 46: 386–392
- Ray K. K., Cannon C. P. Atorvastatin and cardiovascular protection: a review and comparison of recent clinical trials. Expert Opin Pharmacother 2005; 6: 915–927